GlaxoSmithKline Pharmaceuticals Limited has issued a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate, received from Kfin Technologies Limited, their Registrar and Share Transfer Agent, validates the dematerialization of securities. It confirms that dematerialized securities were accepted by depositories, and the original certificates were mutilated and cancelled as per regulations.
Compliance Confirmation for Q1 2026
GlaxoSmithKline Pharmaceuticals Limited has officially submitted a certificate pertaining to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certification covers the financial quarter that concluded on June 30, 2026. The announcement was made on July 8, 2026, and was sent to both the BSE Limited and the National Stock Exchange of India Limited.
Details of Dematerialization Process
The enclosed certificate, provided by Kfin Technologies Limited, acting as the Registrar and Share Transfer Agent for GlaxoSmithKline Pharmaceuticals Limited, confirms the adherence to regulatory requirements. It explicitly states that all securities received from depository participants for the purpose of dematerialization during the quarter ending June 30, 2026, were duly confirmed and processed by Kfin Technologies Limited. Furthermore, it assures that the dematerialized securities have been accepted by the respective depositories and are listed on the stock exchanges where the earlier issued securities were traded.
Cancellation of Physical Certificates
As part of the dematerialization process, the certificate also verifies that all physical security certificates received for dematerialization have been meticulously mutilated and cancelled following thorough verification by the depository participants. Following this cancellation, the names of the depositories have been substituted in the register of members as the registered owners within the stipulated timeframe of 30 days, ensuring compliance and accuracy in shareholding records.
Source: BSE
